<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been performed in this setting have demonstrated superior response rates and increased overall survival, however, they mostly included patients with melanomas carrying the more common V600E and V600K mutations, not being able to assess the benefit of these treatments in situations where more rare mutations of the BRAF gene are present. We present the evolution of a patient with malignant melanoma with a rare V600M mutation in the BRAF gene, that was eventually treated with vemurafenib. Also we present a brief review of the major phase III trials that showed benefit with tyrosine-kinase inhibitors in BRAF mutated melanoma, with respect to the BRAF mutations included.</p></abstract>

Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been performed in this setting have demonstrated superior response rates and increased overall survival, however, they mostly included patients with melanomas carrying the more common V600E and V600K mutations, not being able to assess the benefit of these treatments in situations where more rare mutations of the BRAF gene are present. We present the evolution of a patient with malignant melanoma with a rare V600M mutation in the BRAF gene, that was eventually treated with vemurafenib. Also we present a brief review of the major phase III trials that showed benefit with tyrosine-kinase inhibitors in BRAF mutated melanoma, with respect to the BRAF mutations included.

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review

Medical Oncology Department, “Colentina” Clinical Hospital

Gastroenterology Department, “Colentina” Clinical Hospital

Department of Radiotherapy II, “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology

“Carol Davila” University of Medicine and Pharmacy

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in...

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review

Data publikacji: 17 maj 2018

Zakres stron: 122 - 126

Otrzymano: 15 paź 2017

DOI: https://doi.org/10.1515/rjim-2017-0044

Słowa kluczowe
melanoma, cutaneous malignant, melanoma, protein-tyrosine kinases, vemurafenib, dabrafenib

© 2018 Andrei Popescu et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review

Data publikacji: 17 maj 2018

Zakres stron: 122 - 126

Otrzymano: 15 paź 2017

DOI: https://doi.org/10.1515/rjim-2017-0044

Słowa kluczowemelanoma, cutaneous malignant, melanoma, protein-tyrosine kinases, vemurafenib, dabrafenib

© 2018 Andrei Popescu et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Słowa kluczowe
melanoma, cutaneous malignant, melanoma, protein-tyrosine kinases, vemurafenib, dabrafenib